Graft-versus-host Disease
📧 Sign up to get email alerts when something new happens for Graft-versus-host Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-12-09Clinical Trial Update: Umbilical Cord Mesenchymal Stem Cells in the Treatment of Moderate/Severe Chronic Graft-versus-host Disease [Phase 1, Phase 2]
Early-phase trial investigating umbilical cord mesenchymal stem cells for moderate to severe chronic graft-versus-host disease. Phase 1/2 st…
-
CLINICAL_TRIALS trial_result · 2021-12-01Clinical Trial Update: Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD [Phase 1, Phase 2]
Clinical trial update for chidamide in steroid-resistant or steroid-dependent severe chronic graft-versus-host disease (cGVHD) spanning Phas…
-
CLINICAL_TRIALS trial_result · 2021-09-23Clinical Trial Update: Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT [Phase 2]
Phase 2 trial evaluating sirolimus and mycophenolate mofetil for GVHD prophylaxis in myeloablative matched related donor hematopoietic cell …
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: MTX and Steroid for aGVHD Treatment [Phase 2]
Phase 2 clinical trial update evaluating methotrexate and steroids for acute graft-versus-host disease.
-
CLINICAL_TRIALS trial_result · 2021-09-14Clinical Trial Update: GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide [Phase 1, Phase 2]
Clinical trial evaluating methotrexate for GVHD prophylaxis in haploidentical hematopoietic cell transplantation with post-transplant cyclop…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-09-01Clinical Trial Update: An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD) [Phase 2]
Open-label Phase 2 trial evaluating multiple doses of cannabidiol to prevent acute graft-versus-host disease (aGVHD).
-
CLINICAL_TRIALS trial_result · 2021-08-25Clinical Trial Update: Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD [Phase 4]
Phase 4 trial evaluating basiliximab with ruxolitinib as second-line treatment for grade 3-4 steroid-resistant acute graft-versus-host disea…
-
CLINICAL_TRIALS trial_result · 2021-08-18Clinical Trial Update: An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD) [Phase 2]
Phase 2 open-label study assessing defibrotide for the prevention of acute graft-versus-host disease completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-08-04Clinical Trial Update: T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802) [Phase 3]
Phase 3 trial of T-Guard (Xenikos) for steroid-refractory acute graft-versus-host disease was terminated; results are posted.
-
CLINICAL_TRIALS trial_result · 2021-07-27Clinical Trial Update: Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease [Phase 1, Phase 2]
Phase 1/2 trial evaluating topical fibrinogen-depleted human platelet lysate for dry eye caused by graft-versus-host disease has completed.
-
CLINICAL_TRIALS trial_result · 2021-07-22Clinical Trial Update: Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD [Phase 1, Phase 2]
Phase 1/2 study evaluating IL-22 IgG2-Fc (F-652) for acute graft-versus-host disease (aGVHD) shows results posted after completion.
-
FDA approval · 2021-07-16FDA Approved: REZUROCK — Original Application (Kadmon Pharmaceuticals, LLC)
The FDA approved REZUROCK (belumosudil) from Kadmon Pharmaceuticals, LLC as an original NDA for the treatment of adults with chronic graft-v…
-
FDA approval · 2021-07-16FDA Approved: PROGRAF — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for PROGRAF (tacrolimus) from Astellas Pharma US, expanding or updating its labeling and indications…
-
CLINICAL_TRIALS trial_result · 2021-06-30Clinical Trial Update: Outcomes of Patients After Allo-HSCT With Decitabine and NAC [Phase 3]
Phase 3 trial update on outcomes after allogeneic hematopoietic stem cell transplantation using decitabine and NAC for engraftment failure a…
-
CLINICAL_TRIALS trial_result · 2021-06-23Clinical Trial Update: Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease [Phase 2]
Phase 2 trial update on discontinuation or continuation of immunosuppressive therapy in participants with chronic graft-versus-host disease …
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) [Phase 2]
Phase II trial update on Efprezimod Alfa (CD24Fc, MK-7110) for prevention of acute GVHD after myeloablative allogeneic HSCT; trial completed…
-
CLINICAL_TRIALS trial_result · 2021-06-16Clinical Trial Update: Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease [Phase 2]
Phase 2 trial update for vismodegib in steroid-refractory chronic graft-versus-host disease has been terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2021-05-24Clinical Trial Update: A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD [Phase 2]
Phase 2 pilot trial evaluating alpha-1-antitrypsin for pre-emption of steroid-refractory acute GVHD has been completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2021-05-21Clinical Trial Update: PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT [Phase 2]
Phase 2 trial evaluating PT-CY with or without low-dose ATG for lymphoid malignancies undergoing allogeneic hematopoietic stem cell transpla…
-
CLINICAL_TRIALS trial_result · 2021-05-06Clinical Trial Update: Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation [Phase 3]
Phase 3 trial update on prevention of graft-versus-host disease in patients with advanced leukemia or lymphoma undergoing peripheral stem ce…
-
CLINICAL_TRIALS trial_result · 2021-05-04Clinical Trial Update: Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) [Phase 3]
Phase 3 trial evaluating ibrtutinib in combination with corticosteroids versus placebo with corticosteroids for new onset chronic graft-vers…
-
FDA approval · 2021-03-19FDA Approved: UVADEX — Supplemental Application (Therakos LLC)
FDA approved a supplemental application for UVADEX (methoxsalen) from Therakos LLC.
-
CLINICAL_TRIALS trial_result · 2021-03-17Clinical Trial Update: Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT [Phase 2]
Phase 2 single-centre trial evaluating everolimus as prophylaxis for graft-versus-host disease after post-transplant cyclophosphamide in all…
-
CLINICAL_TRIALS trial_result · 2021-02-26Clinical Trial Update: Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease
A completed clinical trial investigating bridging pediatric and adult biomarkers in graft-versus-host disease with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-02-23Clinical Trial Update: Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer [Phase 2]
Phase 2 clinical trial evaluating fecal microbiota transplantation for treatment of steroid-refractory gastrointestinal acute graft-versus-h…